StockpollyBeta
Get App
Popularity #2,102
CCCC · NASDAQ · Biotechnology

C4 Therapeutics (CCCC)

Develops targeted-protein degraders for oncology through TORPEDO.

$3.35
After-hours close+0.04 (+1.16%)
At close$3.31(+0.30%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue11331215576111167
Cost of revenue220222000020
Gross profit9231013376111147
373935314241363546343233
Research & development283023243233272626252524
11910101210999989
Selling & marketing0−200000000−20
General & administrative111010101210999999
Other expenses−202−2−2−20011000
Operating income−28−37−32−21−28−38−29−29−34−23−28−26
234443322333
Interest income334443322333
Interest expense000000000000
Other non-operating income−2−3−2−4−4−3−3−2−2−3−3−3
Income before tax−26−34−28−18−25−34−26−26−32−20−25−24
Income tax expense100000000000
Net income from continuing operations−27−35−28−18−25−35−26−26−32−20−25−24
Net income−27−35−28−18−25−35−26−26−32−20−25−24
EPS, basic−$0.55−$0.68−$0.41−$0.26−$0.35−$0.49−$0.37−$0.37−$0.44−$0.18−$0.20−$0.18
EPS, diluted−$0.55−$0.68−$0.41−$0.26−$0.35−$0.49−$0.37−$0.37−$0.44−$0.18−$0.20−$0.18
Weighted average shares, basic495168697071717173117126131
Weighted average shares, diluted495168697071717173117126131
EBITDA−24−33−29−16−23−33−26−25−32−20−23−23
Depreciation & amortization220222010020
EBIT−26−34−30−18−25−34−26−26−32−20−25−24